ATCC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ATCC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011832
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ATCC is a nonprofit bioresource center and research organization that provides biological products, technical services and educational programs. The organization acquires, preserves, develops, authenticates, produces, and distributes standard reference microorganisms, cell lines and other materials. Its products include nucleic acids, cells and microorganisms, testing and characterization, cells extracts, culture reagents, quality control strains, proteins and cell extracts. ATCC’s services include production and characterization, biorepository management, testing services, and deposit services. The organization offers custom testing services for mycoplasma detection and human cell line authentication. It serves research and life science industry. The organization also provides storage of biomaterials through its facility. ATCC is headquartered in Manassas, Virginia, the US.

ATCC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ATCC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ATCC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ATCC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ATCC, Medical Devices Deals, 2011 to YTD 2017 8
ATCC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ATCC, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Horizon Discovery Enters Into Licensing Agreement With ATCC 10
ATCC Forms Joint Venture with ILSE 11
BioCision Enters Into Co-Development Agreement With ATCC 12
Promega Enters Into An Agreement With ATCC 13
ATCC Enters Into Co-Development Agreement With Stemgent 14
Licensing Agreements 15
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 15
Biomatrica Enters Into Licensing Agreement With ATCC For DNAstable And RNAstable Reagents 16
ATCC Enters into Licensing Agreement with Baylor College of Medicine 17
ATCC Enters Into Licensing Agreement With Life Technologies For GFP Technology 18
ATCC Enters Into Licensing Agreement With iPS Academia Japan 19
ATCC – Key Competitors 20
ATCC – Key Employees 21
ATCC – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 22
Recent Developments 23
Strategy And Business Planning 23
Apr 21, 2017: ATCC Opens Doors to New High-Tech Biorepository in Gaithersburg, MD 23
Corporate Communications 24
May 12, 2016: ATCC Names Dr. Mindy Goldsborough As Chief Science And Technology Officer 24
Product News 25
Nov 20, 2017: ATCC develops novel in vitro model to investigate drug candidates for cancer metastasis 25
Apr 21, 2016: ATCC Launches Custom Cell Lines Funded By The Michael J. Fox Foundation For Parkinson’S Research 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
ATCC, Pharmaceuticals & Healthcare, Key Facts 2
ATCC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
ATCC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ATCC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ATCC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ATCC, Medical Devices Deals, 2011 to YTD 2017 8
ATCC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Horizon Discovery Enters Into Licensing Agreement With ATCC 10
ATCC Forms Joint Venture with ILSE 11
BioCision Enters Into Co-Development Agreement With ATCC 12
Promega Enters Into An Agreement With ATCC 13
ATCC Enters Into Co-Development Agreement With Stemgent 14
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 15
Biomatrica Enters Into Licensing Agreement With ATCC For DNAstable And RNAstable Reagents 16
ATCC Enters into Licensing Agreement with Baylor College of Medicine 17
ATCC Enters Into Licensing Agreement With Life Technologies For GFP Technology 18
ATCC Enters Into Licensing Agreement With iPS Academia Japan 19
ATCC, Key Competitors 20
ATCC, Key Employees 21
ATCC, Joint Venture 22

★海外企業調査レポート[ATCC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NGEx Resources Inc:企業の戦略・SWOT・財務情報
    NGEx Resources Inc - Strategy, SWOT and Corporate Finance Report Summary NGEx Resources Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • LPL Financial Holdings Inc (LPLA):企業の財務・戦略的SWOT分析
    LPL Financial Holdings Inc (LPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Muang Thai Insurance PCL:企業の戦略・SWOT・財務情報
    Muang Thai Insurance PCL - Strategy, SWOT and Corporate Finance Report Summary Muang Thai Insurance PCL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • ACWA Power Barka SAOG:発電所・企業SWOT分析
    ACWA Power Barka SAOG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employe …
  • Duff & Phelps Corporation:企業のM&A・事業提携・投資動向
    Duff & Phelps Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Duff & Phelps Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Xcel Energy Inc (XEL)-エネルギー分野:企業M&A・提携分析
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • Fauji Fertilizer Bin Qasim Ltd (FFBL):企業の財務・戦略的SWOT分析
    Fauji Fertilizer Bin Qasim Ltd (FFBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • AIG Europe Limited:企業の戦略・SWOT・財務情報
    AIG Europe Limited - Strategy, SWOT and Corporate Finance Report Summary AIG Europe Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • CEZ, AS (CEZ):電力:M&Aディール及び事業提携情報
    Summary CEZ, AS (CEZ) is an integrated energy conglomerate. It extracts and sells coal; generates and distributes electricity and heat; and trades electricity, natural gas, and other commodities. The company generates electricity using nuclear, wind, gas, hydro, coal, solar, and biogas sources. CEZ …
  • Abg Sundal Collier Holding Asa:企業の戦略・SWOT・財務分析
    Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report Summary Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Chimerix Inc (Chimerix) is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir is an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. It als …
  • RKW SE:企業の戦略的SWOT分析
    RKW SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Aurora National Life Assurance Company:企業の戦略・SWOT・財務情報
    Aurora National Life Assurance Company - Strategy, SWOT and Corporate Finance Report Summary Aurora National Life Assurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Westinghouse Electric Co LLC:企業の戦略的SWOT分析
    Westinghouse Electric Co LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • City Developments Ltd:企業の戦略・SWOT・財務分析
    City Developments Ltd - Strategy, SWOT and Corporate Finance Report Summary City Developments Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Minnesota Municipal Power Agency:企業の戦略的SWOT分析
    Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Senomyx Inc (SNMX):企業の財務・戦略的SWOT分析
    Summary Senomyx Inc (Senomyx) focuses on the discovery, development and commercialization of novel flavor ingredients and natural high intensity sweeteners (HIS) to packaged food, beverage and ingredient supply industries. The company discovers and develops novel flavor ingredients and natural HIS t …
  • Cellerant Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Cellerant Therapeutics Inc (Cellerant) develops novel immunotherapies for oncology and blood-related disorders. Its lead product, CLT-008, is a myeloid progenitor cell therapy which is in Phase 2 clinical development in patients with acute myeloid leukemia (AML). Cellerant develops various c …
  • Sany Heavy Industry Co Ltd (600031):企業の財務・戦略的SWOT分析
    Sany Heavy Industry Co Ltd (600031) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Landmarks Berhad:企業の戦略・SWOT・財務情報
    Landmarks Berhad - Strategy, SWOT and Corporate Finance Report Summary Landmarks Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆